Increasing international uncertainties force foreign trade pharmaceutical companies to transform and upgrade

After the blowout growth in 2011, the growth rate of China's pharmaceutical import has entered a relatively stable growth track in the past two years According to the analysis report on logistics mode and investment opportunities of China's pharmaceutical circulation industry issued by prospective industry research institute, the import volume of China's pharmaceutical and health care products in the first half of this year was US $18.093 billion, up 15.01% year on year Among them, the import of API was driven by foreign investment, and some characteristic API procurement was transferred to China The growth rate continued to slow down, with an increase rate of 4.66%, a proportion of 20.76%, and a decrease of 2.1% In the first half of the year, western medicine accounted for 29.28%, up 10.99% year-on-year; the import of diagnosis and treatment equipment was 4.88 billion US dollars, up 11.42% year-on-year It is worth noting that in the first half of this year, multinational pharmaceutical companies are increasing investment in China's biomedicine and diagnostic reagents In the medium and long term, China's position as a global manufacturing factory will not change China has perfect industrial supporting and processing capacity, and the comparative advantage of export enterprises still exists Under this expectation, China's pharmaceutical foreign trade is expected to enter a relatively long and complex period, and the unstable and uncertain factors will increase It is the various adverse factors in the international market that force the transformation and upgrading of Chinese pharmaceutical enterprises The transformation of Chinese Pharmaceutical Foreign trade enterprises is inevitable It is necessary to shift from comparative advantage to competitive advantage, from price competition to brand competition, and from product export to value chain reengineering At present, China's pharmaceutical enterprises are facing many opportunities: the medical reform plan, the 12th Five Year Plan, the aging of population and the introduction of relevant industrial promotion policies, which have created a major period of opportunity for the development of the pharmaceutical industry; in addition, the transfer of international pharmaceutical division is expected to give China more development advantages; the unlimited business opportunities in the international market will promote more enterprises to "go out" and bring China International advantage resources are used by us; emerging markets such as Africa, Russia and Latin America are full of huge market potential Of course, during this period, the pharmaceutical industry will also face more challenges: the impact of uncertain and unstable economic factors at home and abroad; the weak R & D foundation of enterprises, the separation of industry, University, research and trade, and the urgent task of upgrading the industrial structure; the threat of large energy consumption, heavy pollution, resource waste and overcapacity to the sustainable development of the industry; the general lack of practical experience in international operation; medical improvement Cheng's encounter with resistance will affect the healthy development of the industry and face direct competition from India and other countries To this end, the chamber of Commerce of medical insurance believes that the key to solve the problem is to coordinate the policy, to coordinate the industrial policy and trade policy; to coordinate the industrial policy and medical reform policy; to coordinate the promotion policy of "going out" and "bringing in"; to coordinate the foreign aid policy and "going out" policy.